SAFETY DATA SHEET

Mirtazapine Solid Formulation

SECTION 1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Mirtazapine Solid Formulation

Manufacturer or supplier’s details
Company : Organon & Co.
Address : 30 Hudson Street, 33nd floor
Jersey City, New Jersey, U.S.A 07302
Telephone : 551-430-6000
Emergency telephone : 215-631-6999
E-mail address : EHSSTEWARD@organon.com

Recommended use of the chemical and restrictions on use
Recommended use : Pharmaceutical

SECTION 2. HAZARDS IDENTIFICATION

GHS Classification
Acute toxicity (Oral) : Category 5
Reproductive toxicity : Category 2
Specific target organ toxicity - repeated exposure (Oral) : Category 2 (Nervous system)
Short-term (acute) aquatic hazard : Category 3
Long-term (chronic) aquatic hazard : Category 3

GHS label elements
Hazard pictograms :

Signal Word : Warning
Hazard Statements : H303 May be harmful if swallowed.
H361fd Suspected of damaging fertility. Suspected of damaging the unborn child.
H373 May cause damage to organs (Nervous system) through prolonged or repeated exposure if swallowed.
H412 Harmful to aquatic life with long lasting effects.
Precautionary Statements:

**Prevention:**
- P201 Obtain special instructions before use.
- P202 Do not handle until all safety precautions have been read and understood.
- P260 Do not breathe dust.
- P273 Avoid release to the environment.
- P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

**Response:**
- P312 Call a POISON CENTER/ doctor if you feel unwell.

**Storage:**
- P405 Store locked up.

**Disposal:**
- P501 Dispose of contents/ container to an approved waste disposal plant.

**Other hazards which do not result in classification**
Dust contact with the eyes can lead to mechanical irritation.
Contact with dust can cause mechanical irritation or drying of the skin.
May form explosive dust-air mixture during processing, handling or other means.

### SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

**Substance / Mixture:** Mixture

<table>
<thead>
<tr>
<th>Components</th>
<th>Chemical name</th>
<th>CAS-No.</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(+/-)-1,2,3,4,10b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine</td>
<td>85650-52-8</td>
<td>&gt;= 10 -&lt; 20</td>
</tr>
<tr>
<td></td>
<td>Starch</td>
<td>9005-25-8</td>
<td>&gt;= 10 -&lt; 20</td>
</tr>
</tbody>
</table>

### SECTION 4. FIRST AID MEASURES

**General advice**:
In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.

**If inhaled**:
If inhaled, remove to fresh air.
Get medical attention.

**In case of skin contact**:
In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.

**In case of eye contact**:
If in eyes, rinse well with water.
Get medical attention if irritation develops and persists.

**If swallowed**:
If swallowed, DO NOT induce vomiting.
### SAFETY DATA SHEET

**Mirtazapine Solid Formulation**

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date:</th>
<th>SDS Number:</th>
<th>Date of last issue:</th>
<th>Date of first issue:</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.3</td>
<td>23.03.2020</td>
<td>51079-00015</td>
<td>13.09.2019</td>
<td>23.01.2015</td>
</tr>
</tbody>
</table>

**Section 5. Fire-fighting Measures**

**Most important symptoms and effects, both acute and delayed:**
- Get medical attention. Rinse mouth thoroughly with water.
- May be harmful if swallowed.
- Suspected of damaging fertility. Suspected of damaging the unborn child.
- May cause damage to organs through prolonged or repeated exposure if swallowed.
- Contact with dust can cause mechanical irritation or drying of the skin.
- Dust contact with the eyes can lead to mechanical irritation.

**Protection of first-aiders:**
- First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

**Notes to physician:**
- Treat symptomatically and supportively.

**Suitable extinguishing media:**
- Water spray
- Alcohol-resistant foam
- Carbon dioxide (CO2)
- Dry chemical

**Unsuitable extinguishing media:**
- None known.

**Specific hazards during fire fighting:**
- Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.
- Exposure to combustion products may be a hazard to health.

**Hazardous combustion products:**
- Carbon oxides
- Silicon oxides

**Specific extinguishing methods:**
- Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
- Use water spray to cool unopened containers.
- Remove undamaged containers from fire area if it is safe to do so.
- Evacuate area.

**Special protective equipment for fire-fighters:**
- In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

### Section 6. Accidental Release Measures

**Personal precautions, protective equipment and emergency procedures:**
- Use personal protective equipment.
- Follow safe handling advice and personal protective equipment recommendations.

**Environmental precautions:**
- Discharge into the environment must be avoided.
- Prevent further leakage or spillage if safe to do so.
- Retain and dispose of contaminated wash water.
- Local authorities should be advised if significant spillages cannot be contained.

**Methods and materials for containment and cleaning up:**
- Sweep up or vacuum up spillage and collect in suitable container for disposal.
- Avoid dispersal of dust in the air (i.e., clearing dust surfaces...
with compressed air). Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures: Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation: Use only with adequate ventilation.

Advice on safe handling: Do not breathe dust. Do not swallow. Avoid contact with eyes. Avoid prolonged or repeated contact with skin. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition. Take precautionary measures against static discharges. Take care to prevent spills, waste and minimize release to the environment.

Conditions for safe storage: Keep in properly labeled containers. Store locked up. Store in accordance with the particular national regulations.

Materials to avoid: Do not store with the following product types: Strong oxidizing agents

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine</td>
<td>85650-52-8</td>
<td>TWA</td>
<td>25 µg/m³</td>
<td>Internal</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Wipe limit</td>
<td>250 µg/100 cm²</td>
</tr>
<tr>
<td>Starch</td>
<td>9005-25-8</td>
<td>CMP</td>
<td>10 mg/m³</td>
<td>AR OEL</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Further information: A4 - Not classifiable as a human carcinogen, lung, Dermatitis</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>TWA</td>
<td>10 mg/m³</td>
</tr>
</tbody>
</table>
Engineering measures:
Ensure adequate ventilation, especially in confined areas. Minimize workplace exposure concentrations. Apply measures to prevent dust explosions. Ensure that dust-handling systems (such as exhaust ducts, dust collectors, vessels, and processing equipment) are designed in a manner to prevent the escape of dust into the work area (i.e., there is no leakage from the equipment).

Personal protective equipment:

Respiratory protection:
If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type: Particulates type

Hand protection:
Material: Chemical-resistant gloves

Remarks:
Choose gloves to protect hands against chemicals depending on the concentration specific to place of work. Breakthrough time is not determined for the product. Change gloves often! For special applications, we recommend clarifying the resistance to chemicals of the aforementioned protective gloves with the glove manufacturer. Wash hands before breaks and at the end of workday.

Eye protection:
Wear the following personal protective equipment:
Safety goggles

Skin and body protection:
Select appropriate protective clothing based on chemical resistance data and an assessment of the local exposure potential. Skin contact must be avoided by using impervious protective clothing (gloves, aprons, boots, etc).

Hygiene measures:
If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance: powder
Color: No data available
Odor: No data available
Odor Threshold: No data available
pH: No data available
Melting point/freezing point: No data available
Initial boiling point and boiling range: No data available
SAFE DATA SHEET

Mirtazapine Solid Formulation

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date</th>
<th>SDS Number</th>
<th>Date of last issue</th>
<th>Date of first issue</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.3</td>
<td>23.03.2020</td>
<td>51079-00015</td>
<td>13.09.2019</td>
<td>23.01.2015</td>
</tr>
</tbody>
</table>

- **Flash point**: Not applicable
- **Evaporation rate**: No data available
- **Flammability (solid, gas)**: May form explosive dust-air mixture during processing, handling or other means.
- **Flammability (liquids)**: No data available
- **Upper explosion limit / Upper flammability limit**: No data available
- **Lower explosion limit / Lower flammability limit**: No data available
- **Vapor pressure**: No data available
- **Relative vapor density**: No data available
- **Relative density**: No data available
- **Density**: No data available
- **Solubility(ies)**
  - **Water solubility**: No data available
- **Partition coefficient: n-octanol/water**: No data available
- **Autoignition temperature**: No data available
- **Decomposition temperature**: No data available
- **Viscosity**
  - **Viscosity, dynamic**: No data available
  - **Viscosity, kinematic**: No data available
- **Explosive properties**: Not explosive
- **Oxidizing properties**: The substance or mixture is not classified as oxidizing.
- **Molecular weight**: No data available
- **Particle size**: No data available

**SECTION 10. STABILITY AND REACTIVITY**

- **Reactivity**: Not classified as a reactivity hazard.
- **Chemical stability**: Stable under normal conditions.
- **Possibility of hazardous reactions**
  - **May form explosive dust-air mixture during processing, handling or other means.** Can react with strong oxidizing agents.
 Conditions to avoid : Heat, flames and sparks.
                 Avoid dust formation.

 Incompatible materials : Oxidizing agents

 Hazardous decomposition products : No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure:
- Inhalation
- Skin contact
- Ingestion
- Eye contact

Acute toxicity
May be harmful if swallowed.

Product:
Acute oral toxicity : Acute toxicity estimate: 3,200 mg/kg
                      Method: Calculation method

Components:
(+/-)-1,2,3,4,10b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:
Acute oral toxicity : LD50 (Rat): 320 - 490 mg/kg

Starch:
Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg
Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Skin corrosion/irritation
Not classified based on available information.

Serious eye damage/eye irritation
Not classified based on available information.

Components:
Starch:
Species : Rabbit
Result : No eye irritation

Respiratory or skin sensitization

Skin sensitization
Not classified based on available information.

Respiratory sensitization
Not classified based on available information.

Components:
Starch:
Test Type : Maximization Test
Routes of exposure: Skin contact
Species: Guinea pig
Result: negative

**Germ cell mutagenicity**
Not classified based on available information.

**Components:**

\((+/\text{-})1,2,3,4,10,14\text{b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:}\)

**Genotoxicity in vitro**
- Test Type: Bacterial reverse mutation assay (AMES)
  Result: negative
- Test Type: In vitro mammalian cell gene mutation test
  Test system: Chinese hamster lung cells
  Result: negative
- Test Type: unscheduled DNA synthesis assay
  Test system: mammalian cells
  Result: negative
- Test Type: sister chromatid exchange assay
  Test system: mammalian cells
  Result: negative

**Genotoxicity in vivo**
- Test Type: Micronucleus test
  Species: Rat
  Cell type: Bone marrow
  Application Route: Oral
  Result: negative

**Starch:**

**Genotoxicity in vitro**
- Test Type: Bacterial reverse mutation assay (AMES)
  Result: negative

**Carcinogenicity**
Not classified based on available information.

**Components:**

\((+/\text{-})1,2,3,4,10,14\text{b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:}\)

Species: Mouse
Application Route: Oral
Exposure time: 18 month(s)
LOAEL: 200 mg/kg body weight
Result: equivocal
Target Organs: Liver

Species: Rat
Application Route: Oral
Exposure time: 2 Years
LOAEL: 20 mg/kg body weight
Result: equivocal
Target Organs: Liver, Thyroid
Reproductive toxicity
Suspected of damaging fertility. Suspected of damaging the unborn child.

Components:
(+/-)1,2,3,4,10b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:

Effects on fertility:
- Test Type: Fertility/early embryonic development
- Species: Rat
- Application Route: Oral
- Fertility: LOAEL: 15 mg/kg body weight
- Symptoms: Effect on estrous cycle, Increase of early resorptions.
- Result: Animal testing did not show any effects on fertility., Embryotoxic effects and adverse effects on the offspring were detected.

Effects on fetal development:
- Test Type: Development
- Species: Rat
- Application Route: Oral
- Developmental Toxicity: LOAEL: 100 mg/kg body weight
- Result: Embryotoxic effects and adverse effects on the offspring were detected., No teratogenic effects.

Test Type: Development
- Species: Rabbit
- Application Route: Oral
- Developmental Toxicity: NOAEL: 40 mg/kg body weight
- Result: No adverse effects., No teratogenic effects.

Reproductive toxicity - Assessment:
- Some evidence of adverse effects on sexual function and fertility, based on animal experiments., Some evidence of adverse effects on development, based on animal experiments.

STOT-single exposure
Not classified based on available information.

STOT-repeated exposure
May cause damage to organs (Nervous system) through prolonged or repeated exposure if swallowed.

Components:
(+/-)1,2,3,4,10b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:

Routes of exposure: Ingestion
Target Organs: Nervous system
Assessment: May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:
(+/-)1,2,3,4,10b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:
Species: Rat  
LOAEL: 120 mg/kg  
Application Route: Oral  
Exposure time: 13 Weeks  
Target Organs: Nervous system

Species: Dog  
LOAEL: 15 mg/kg  
Application Route: Oral  
Exposure time: 52 Weeks  
Target Organs: Nervous system

Symptoms: Tremors

Species: Dog  
LOAEL: 20 mg/kg  
Application Route: Oral  
Exposure time: 13 Weeks  
Target Organs: Nervous system, Testis

Symptoms: Tremors

Starch:
Species: Rat  
NOAEL: >= 2.000 mg/kg  
Application Route: Skin contact  
Exposure time: 28 Days

Method: OECD Test Guideline 410

Aspiration toxicity
Not classified based on available information.

Experience with human exposure

Components:
(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:
Ingestion: Symptoms: Drowsiness, constipation, dry mouth, asthenia, Dizziness, Disorientation

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:
(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:
Toxicity to fish: LC50 (Pimephales promelas (fathead minnow)): 6,92 mg/l  
Exposure time: 96 h

Method: FDA 4.11

Toxicity to daphnia and other aquatic invertebrates: EC50 (Daphnia magna (Water flea)): 19,5 mg/l  
Exposure time: 48 h

Toxicity to algae/aquatic plants: EC50 (Pseudokirchneriella subcapitata (green algae)): 5,7 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 3,2 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

Toxicity to fish (Chronic toxicity)
NOEC (Pimephales promelas (fathead minnow)): 3,6 mg/l
Exposure time: 31 d
Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)
NOEC (Daphnia magna (Water flea)): 0,32 mg/l
Exposure time: 21 d
Method: OECD Test Guideline 211

Toxicity to microorganisms
EC50 (Natural microorganism): > 1.000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

NOEC (Natural microorganism): < 100 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

Persistence and degradability
No data available

Bioaccumulative potential

Components:

(+/-)-1,2,3,4,10b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:

Bioaccumulation:
Species: Oncorhynchus mykiss (rainbow trout)
Bioconcentration factor (BCF): 334
Method: OECD Test Guideline 305

Partition coefficient: n-octanol/water
log Pow: 2,78

Mobility in soil

Components:

(+/-)-1,2,3,4,10b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:

Distribution among environmental compartments
log Koc: 4,48

Other adverse effects
No data available
SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods
Waste from residues : Dispose of in accordance with local regulations.
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations
UNRTDG
Not regulated as a dangerous good
IATA-DGR
Not regulated as a dangerous good
IMDG-Code
Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code
Not applicable for product as supplied.

SECTION 15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture
Argentina. Carcinogenic Substances and Agents Registry.
: Not applicable

Control of precursors and essential chemicals for the preparation of drugs.
: Not applicable

International Regulations
The ingredients of this product are reported in the following inventories:
AICS : not determined
DSL : not determined
IECSC : not determined

SECTION 16. OTHER INFORMATION

Further information

Full text of other abbreviations
The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.